TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01081158
Drug: Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension + ritonavir (200 mg BID) (2-100 mg oral capsules) for 7 days.~Period 2: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension+ ritonavir (200 mg BID) (2-100 mg oral capsules) + PegIntron (1.5 µg/kg QW) for 14 days.
Study: NCT01081158
Drug: Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug: SCH 900518~Drug: Ritonavir (RTV)~Biologic: Peginterferon alfa-2b (PegIntron)~Period 1, Amorphous SCH 900518 (400 mg) or placebo BID administered as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) for 7 days.~Period 2, SCH 900518 (400 mg) or placebo BID as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) +PegIntron (1.5 µg/kg SC QW) for 14 days.
Study: NCT00067561
Drug: Alosetron
Normalized name: Alosetron
DrugBank: Alosetron (DB00969)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02685397
Drug: Leuprolide Acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
Study: NCT02685397
Drug: Goserelin Acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
Study: NCT02685397
Drug: Triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
Study: NCT02685397
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anti-androgen medication for the treatment of metastatic castration-resistant prostate cancer. 160 mg (four 40 mg capsules) taken as a single oral daily dose, with or without food, until disease progression.
Study: NCT04188951
Drug: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
Normalized name: Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive 17 cycles of pembrolizumab via IV infusion of 200 mg over a period of 30 minutes, every 3 weeks starting no later than 90 days from the date of salvage head and neck therapy.
Study: NCT01911351
Drug: Nitrous Oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomized to the intervention arm will receive nitrous oxide plus standard management for their minor procedure.
Study: NCT00287781
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00943761
Drug: Vaniprevir 600 mg b.i.d.
DrugBank: Vaniprevir (DB11929)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral capsules containing 150 mg vaniprevir, four in the morning and four in the evening, for 48 weeks
Study: NCT00943761
Drug: Vaniprevir 300 mg b.i.d.
DrugBank: Vaniprevir (DB11929)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Oral capsules containing 150 mg vaniprevir, two in the morning and two in the evening, for 48 weeks
Study: NCT00943761
Drug: Pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prefilled syringe containing 180 µg/0.5 mL peg-IFN, for weekly subcutaneous injection, for 48 weeks
Study: NCT00943761
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tablets containing 200 mg RBV, 5 or 6 tablets, dosage based on the participant's weight (\<75 kg or ≥75 kg, respectively), for 48 weeks
Study: NCT01708044
Drug: Pramlintide acetate
Normalized name: Pramlintide Acetate
DrugBank: Pramlintide (DB01278)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04841993
Drug: Cannabis decoction
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single 100 mL dose of cannabis decoction is administered containing 1.8 mg THC and 2.7 mg CBD.
Study: NCT04841993
Drug: Vaporized cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100mg of vaporized cannabis is administered by Volcano vaporizer, wich containing 0.6-2 mg THC and 0.8-3 mg CBD
Study: NCT00444106
Drug: Artesunate-mefloquine
Normalized name: artesunate and mefloquine
DrugBank: Mefloquine (DB00358)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00444106
Drug: Atovaquone-proguanil
Normalized name: atovaquone-proguanil
DrugBank: Atovaquone (DB01117)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02004301
Drug: Radiolabelled T4 Tablet
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02004301
Drug: Radiolabelled T6 Tablet
Normalized name: Radiolabelled DUNP19
DrugBank: RAD 502 (DB17328)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01166035
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide will be supplied as 5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules for oral administration.~Prior to Cycle 1, there will be a 21 day lead in treatment period with lenalidomide monotherapy (Days -21 to -1). Combination treatment will start at Day 1. Subjects will be enrolled in cohorts of three to receive a single, oral dose of lenalidomide administered on Days 1-28. For each cohort of subjects, the decision of whether or not to dose-escalate will be made after subjects have received the first treatment cycle of study drug. Treatment will continue until the occurrence of any of the following events.~* Disease progression~* Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.~* Major violation of the study protocol.~* Withdrawal of consent~* Lost to follow up~* Death~* Suspected pregnancy
Study: NCT01166035
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combination treatment will start at Day 1. Subjects meeting will be enrolled in cohorts of three to receive infusions of cetuximab (400 mg/m2 first infusion only, then 250 mg/m2 subsequently) administered on Days 1, 8, 15, and 22 of each 28-day cycle. Cetuximab will be supplied as Erbitux® 22 mg/ml Vial à 50 ml, Erbitux 5 mg/ml Vial à 10 ml and Erbitux 5 mg/ml Vial à 50 ml for intravenous administration.~Treatment will continue until the occurrence of any of the following events.~* Disease progression~* Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.~* Major violation of the study protocol.~* Withdrawal of consent~* Lost to follow up~* Death~* Suspected pregnancy
Study: NCT01900665
Drug: Solanezumab
Normalized name: Solanezumab
DrugBank: Solanezumab (DB11756)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered Intravenously (IV)
Study: NCT02366325
Drug: EPO-018B
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00076440
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00001937
Drug: FK463
Normalized name: Micafungin
DrugBank: Micafungin (DB01141)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001937
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01039389
Drug: Ivabradine
Normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bid administration of 5mg ivabradine (max 7.5mg) aiming to reduce resting heart rate to 60/min
Study: NCT01079312
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol 10 mg/ml solution is a short-acting, intravenously administered hypnotic agent.In propofol infusion group moderate sedation was initiated with propofol 40 mg bolus,thereafter propofol infusion was started at rate of 0.5 mg/kg/h.If the performance of ERCP become difficult infusion rate was increased gradually ad maximum rate of 9 mg/kg/h.Additional propofol boluses of 20-40 mg were available in both groups due to an anaesthesiollogist´s ´desigion.In patient-controlled sedation group propofol was used for preparation of sedative mixture.
Study: NCT02224534
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose
Study: NCT02224534
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clopidogrel 600 mg as a loading dose and 75 mg once daily as a maintenance dose.
Study: NCT01127620
Drug: Bilastine
Normalized name: bilastine
DrugBank: Bilastine (DB11591)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 20 mg encapsulated tablets
Study: NCT01127620
Drug: Cetirizine
Normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg encapsulated tablets
Study: NCT00882024
Drug: Tranilast
Normalized name: Tranilast
DrugBank: Tranilast (DB07615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg tranilast tablets, bid, 12 weeks
Study: NCT00882024
Drug: Tranilast
Normalized name: Tranilast
DrugBank: Tranilast (DB07615)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg tablets, bid, 12 weeks
Study: NCT03261921
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone is used peri -operatively mainly to prevent nausea and vomiting. Also epidural administration of dexamethasone prolong the postoperative analgesia and reduce analgesic needs
Study: NCT03261921
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine is an alpha 2 agonist which has sedative ,analgesic, opioid sparing effect and was proved to prolong the duration of postoperative analgesia when added to local anesthetics
Study: NCT03261921
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: local anesthetic agent
Study: NCT03402100
Drug: eye drops
Normalized name: Eye Drops
DrugBank: Tetryzoline (DB06764)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: children who received daily eye drops for myopia
Study: NCT01310010
Drug: dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Treatment with 100 mg QD of dasatinib (Sprycel®) administered orally as continuous daily dosing (CDD).
Study: NCT03655847
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine was injected intravenously 30 minutes before the end of operation. Single bolus is for more than 1 minute. In the first case, the dosage of dexmedetomidine was 0.1 ug/kg. If the cardiovascular reaction was positive (mean arterial pressure or heart rate was more than 20% before intravenous injection), the dosage of Dexmedetomidine in the next patient decreased by a gradient (0.05ug/kg). If the cardiovascular response was negative, the next patient increased the dose of dexmedetomidine by a gradient (0.1ug/kg); if a patient withdrew from the study, the next patient received the same dose as the patient who withdrew.
Study: NCT02590289
Drug: BBI-5000
Normalized name: BBIBP-CorV
DrugBank: BBIBP-CorV (DB15807)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBI-5000 low dose, middle dose, or high doses
Study: NCT00005935
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005935
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00953706
Drug: Ivacaftor
Normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet
Study: NCT03351348
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention in this study is the insertion of 20cc of 0.5% bupivacaine via a drain into the mastectomy wound for 2 hours ± 30 minutes postoperatively in patients undergoing unilateral mastectomy without breast reconstruction +/- SLNB, +/- axillary dissection.
Study: NCT00665353
Drug: pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditionally used in the treatment of type 2 diabetes to increase insulin sensitivity. Participants will take 30 mg daily in tablet form.
Study: NCT00665353
Drug: peginterferon
Normalized name: PEGINTERFERON
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Used in the treatment of HCV. Participants will receive 180 mcg subcutaneously once a week.
Study: NCT00665353
Drug: ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Used in the treatment of HCV. Participants will receive 1000 to 1200 mg orally per day depending on weight.
Study: NCT02015780
Drug: Fasiglifam
Normalized name: Fasiglifam
DrugBank: Fasiglifam (DB12491)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasiglifam tablets
Study: NCT03678532
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04052269
Drug: Sildenafil 100mg
Normalized name: sildenafil 100 MG
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: study drug (Sildenafil or Tadalafil) administered orally in pill form with glass of water.
Study: NCT01734330
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00660582
Drug: Cetuximab (Erbitux)
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 500 mg/m² every second week, intravenous infusion, 8 cycles
Study: NCT01594242
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01101529
Drug: Aprepitant (Emend)
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant will be added to the standard anti-emetic therapy. Emend is given orally, 125 mg the first day, then 80 mg daily during the chemotherapy course and 7 days after
Study: NCT02175186
Drug: ALBIS
Normalized name: Melilotus albus pollen
DrugBank: Melilotus albus pollen (DB10858)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02224170
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 2mg Kg-1 in normal saline (total volume 25mL) was infused after tracheal intubation, and lidocaine was infused at the rate of lidocaine 2mg Kg-1 h-1 (0.2 ml Kg-1 h-1, equivalent volume as normal saline in dexamethasone group) until the end of surgery (at the time of skin closure).
Study: NCT02224170
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 8mg in normal saline (total volume 25mL) was infused after tracheal intubation, and normal saline was continuously infused at the rate of 0.2 ml Kg-1 h-1 until the end of surgery (at the time of skin closure).
Study: NCT03672630
Drug: Ethambutol
Normalized name: Ethambutol
DrugBank: Ethambutol (DB00330)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethambutol 25 mg/kg \[MYAMBUTOL\]
Study: NCT03672630
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 MG \[RIFADIN\]
Study: NCT02122380
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin 100 mg by mouth daily for 30 Days
Study: NCT01783444
Drug: Exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exemestane, tablets for oral use, 25 mg per day in (locally supplied)
Study: NCT01783444
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus, 5 mg tablets for oral use, 10 mg (2 x 5 mg) per day (centrally supplied)
Study: NCT00937495
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg given PO
Study: NCT00937495
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1.3 mg/m\^2 given IV
Study: NCT01964183
Drug: tolterodine
Normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT01964183
Drug: mirabegron
Normalized name: Mirabegron
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT04118829
Drug: Perampanel
Normalized name: Perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For group 1 the PER dose will be administered 2-14 hours prior to sample collection. They will be administered a single dose of PER (8 mg, 12 mg or 16 mg) followed by 4 mg/day for 14 days starting on postoperative day 1 (if continued prophylaxis with PER is needed).~It is anticipated that patients in group 2 will have the daily dose of PER in these individuals will range from 4 - 12 mg/day.
Study: NCT01581684
Drug: BI 411034
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose solution for oral administration
Study: NCT01581684
Drug: BI 411034
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose solution for oral administration
Study: NCT01581684
Drug: BI 411034
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose solution for oral administration
Study: NCT00003614
Drug: estramustine phosphate sodium
Normalized name: Estramustine Phosphate Sodium
DrugBank: Estramustine (DB01196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003614
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01042314
Drug: Donepezil
Normalized name: Donepezil
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 5 mg, Once Daily, Days 1-28
Study: NCT01042314
Drug: BMS-708163
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Capsule, Oral, 125 mg, Once Daily, Days 15-28
Study: NCT01628913
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 10 mg qd p.o. (by mouth, daily)
Study: NCT04592341
Drug: Gantenerumab
Normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gantenerumab will be administered by SC injection at a dose of 120 mg Q4W for 12 weeks, followed by 255 mg Q4W for 12 weeks, and 255 mg Q2W for another 12 weeks, followed by the target dose 255 mg Q1W for up to Week 103 and an optional dose of 255 mg Q1W for up to Week 207.
Study: NCT01652781
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5-day arm: azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care 7-day arm: azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
Study: NCT00090376
Drug: GPI 1485
Normalized name: GPI-1485
DrugBank: GPI-1485 (DB05814)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00560508
Drug: Pramipexole Immediate Release
Normalized name: pramipexole Extended Release Oral Tablet
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: titrated as individually needed (0.25 mg - 4.5 mg daily)
Study: NCT00560508
Drug: Pramipexole Extended Release
Normalized name: pramipexole Extended Release Oral Tablet
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: titration as individually needed (0.375 mg -4.5 mg daily)
Study: NCT01248793
Drug: Golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab 50 mg SC injection every 4 weeks for 48 weeks
Study: NCT01248793
Drug: Golimumab (placebo group)
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab with early escape at Week 16, 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48
Study: NCT03334838
Drug: Nifurtimox (Lampit, BAYA2502)
Normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Intake of 4 x 30 mg nufurtimox tablets for treatment A-D; Oral Intake of 8 x 30 mg nufurtimox tablets for treatment E.
Study: NCT01102595
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles.~* Temozolomide 75 mg/m2/d x 42-49 days~* Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles.
Study: NCT01102595
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * 2 cycles + bevacizumab 10 mg/kg every 15 days each two cycles.~* Bevacizumab 10 mg/kg every 15 days, three dosis.
Study: NCT01446874
Drug: 0.12% chlorhexidine solution
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution and for the duration of the hospitalization or 5 days postoperatively.
Study: NCT00638729
Drug: midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: midazolam, 7.5 mg p.o., 60-90 min prior to estimated induction time
Study: NCT00638729
Drug: clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pre-anesthetic medication with clonidine, 150 µg p.o., 60-90 min prior to estimated induction time